Nippon Medical School

Development of "VR hands on training" with hand tracking in live-action medical VR!

Retrieved on: 
Thursday, November 18, 2021

This is a VR clinical training platform developed and provided by Jolly Good, where hand tracking sensors are used to superimpose the VR user's hands onto realistic live-action medical procedures in VR.

Key Points: 
  • This is a VR clinical training platform developed and provided by Jolly Good, where hand tracking sensors are used to superimpose the VR user's hands onto realistic live-action medical procedures in VR.
  • Hands on learning will empower practical training exercises in addition to live-action medical VR.
  • OPECloud VR hands on training PV: https://youtu.be/_n40az_cVcw
    VR, which enables active learning, supplements clinical education where training opportunities have been drastically reduced due to the pandemic.
  • With VR, users can become a surgeon and actually move their own hands and body to get a sense of the experience.

Aruvant Announces ARU-2801 Data Oral Presentation at Society for Endocrinology BES 2021 Conference

Retrieved on: 
Tuesday, October 26, 2021

NEW YORK and BASEL, Switzerland, Oct. 26, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced an oral presentation at the Society for Endocrinology BES 2021 conference in Edinburgh, Scotland.

Key Points: 
  • NEW YORK and BASEL, Switzerland, Oct. 26, 2021 /PRNewswire/ -- Aruvant Sciences ("Aruvant"), a private company focused on developing gene therapies for rare diseases, announced an oral presentation at the Society for Endocrinology BES 2021 conference in Edinburgh, Scotland.
  • "The data being presented at SfE BES 2021 support the development of ARU-2801 as a new, one-time treatment option for patients with HPP," said Will Chou, M.D., chief executive officer of Aruvant.
  • This data suggests that using ARU-2801, an AAV gene therapy, may provide durable clinical benefit to HPP patients after a single injection.
  • Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy.

Aruvant Announces ARU-2801 Data Presentations at the American Society for Bone and Mineral Research (ASBMR) 2021 Annual Meeting

Retrieved on: 
Monday, September 20, 2021

Preclinical research showstreatment with ARU-2801results in sustained elevation of tissue non-specific alkaline phosphatase (TNAP), the missing enzyme in HPP, at levels that ameliorate disease symptoms.

Key Points: 
  • Preclinical research showstreatment with ARU-2801results in sustained elevation of tissue non-specific alkaline phosphatase (TNAP), the missing enzyme in HPP, at levels that ameliorate disease symptoms.
  • "The data being presented at ASBMR support the development of ARU-2801 as a new, one-time treatment option for patients with HPP," said Will Chou, M.D., chief executive officer of Aruvant.
  • Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy.
  • For more information on the ongoing ARU-1801 clinical study, please visit www.momentumtrials.com and for more on the company, pleasevisit www.aruvant.com .

Rapid acceleration of medical education for Japan's medical students using VR - NHK special feature published online

Retrieved on: 
Thursday, September 2, 2021

Efforts by Jolly Good and Nippon Medical School to develop the OPEcloud VR clinical education platform were recently featured on NHK WORLD-JAPAN.

Key Points: 
  • Efforts by Jolly Good and Nippon Medical School to develop the OPEcloud VR clinical education platform were recently featured on NHK WORLD-JAPAN.
  • This feature is available to the public online.
  • Also, in the field of nursing student education, 706 (96.6%) of 731 nursing training schools experienced lack of availability for clinical training intake.
  • Jolly Good is a medical technology company that develops high-precision VR solutions and AI-based medical and welfare services that analyze user behavior in the VR space.